India Registration Timeline Planning: Statutory Time Limits versus Actual Duration

1. Key takeaways

Planning the timeline for medical device registration in India requires keeping statutory time limits and actual elapsed time in two separate columns. The statutory limits are clearly written into the rules: the import licence carries a nine-month review period (Rule 36(1), that is, 270 days); the Class B manufacturing licence carries 140 days, and the Class C/D manufacturing licence carries 105 days. Actual elapsed time, however, is the sum of those statutory clocks plus everything the rules do not measure: dossier preparation, the PoA certification chain, the round trips of deficiency clarification, and, where no six-jurisdiction FSC exists, the full clinical investigation period on top. A plan built only on the statutory numbers will always be optimistic, and experience bears this out on every project. The gap between the plan and reality widens precisely where the framework is silent — in applicant-side preparation and in the unbounded clarification cycle. Reading the statutory figures correctly also matters: several of them decompose into stacked sub-limits with different owners, and a schedule that treats a composite figure as a single runway will misjudge who controls which portion of the calendar and where the project can actually be accelerated. The table below collects the statutory figures and their sources so that the two columns — what the rules guarantee and what the calendar will really show — can be compared line by line during planning.

2. Legal basis

The table below lists the statutory timelines, their rule sources, the draft amendment that proposes to compress the manufacturing timelines, and two supporting timelines that appear in official guidance.

3. Expert insights

Insight one: the statutory limit is the government-side clock and excludes the company side. The nine months of Rule 36(1) run from the date of the application, and everything before that date — the classification request, the notarisation and legalisation of the PoA, the three-batch performance evaluation report, the drafting of the DMF and PMF — falls entirely outside those nine months. A project plan that starts counting on the day the decision to enter India is made has already overstated the regulatory portion of the calendar.

Insight two: clarification is the largest variable. The rules set no fixed number of days for responding to queries, so the “deficiency window” familiar from other markets simply does not exist in India as a bounded, predictable period. The slower the company-side response, the longer the total cycle becomes, and there is no time-limit provision on which the applicant can found a claim; the discipline has to come from the project team’s own response standards.

Insight three: one category of project has no statutory time protection at all — and neither does the regulator have extension room. According to the analysis of MDR 2017 (Nishith Desai, third-level source), unlike the Drugs and Cosmetics Rules, MDR 2017 leaves the authority no room to extend its timelines — which is one of India’s strengths. But the same rigidity cuts both ways: a rejection is a rejection; there is no intermediate state of “waiting for an extension” in which the file lingers. The clock either produces a decision on time, or the matter is closed against the applicant.

Insight four: the 2026 draft touches manufacturing only, not import. G.S.R. 515(E) amends Rules 20, 21, 23 and 25, all of which sit on the manufacturing licence chain. The nine-month import licence period is unchanged in the draft (if the draft is finalised, this sentence must be revised in step), so import timelines should not be re-planned on the strength of the draft.

4. Practical recommendations

• Schedule every customer project on a “three stretches plus two variables” model: the stretches are dossier preparation, the statutory review period, and the clarification buffer; the variables are whether a clinical investigation is needed (Class C/D without a six-jurisdiction FSC) and whether an overseas site inspection may be triggered.
• Write this schedule into the service-period clause of the project contract, and agree that time lost through delays in customer-side materials does not count against the service period — a provision that protects both parties equally.
• Track the G.S.R. 515(E) draft as a separate workstream: monitor whether it proceeds to finalisation, and keep the current statutory figures in all live plans until it does.
• Start the applicant-side countdown items (PoA chain, PER batches, dossier drafting) at project kick-off, since none of them enjoy any statutory cover and all of them consume calendar time.
• Set internal response standards for clarification letters, because in India the only control over the clarification variable is the applicant’s own speed.

5. Verification checklist

• □ The schedule has been built as three stretches: preparation plus statutory review plus clarification
• □ It has been confirmed whether a clinical investigation is required first (adding more than six months)
• □ The likelihood of triggering an overseas site inspection has been assessed
• □ The PoA notarisation and legalisation chain time has been included in the plan
• □ Whether the G.S.R. 515(E) draft has been finalised is being tracked (draft not in force)

Regulatory information verified as of October 27, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com